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data, its related phenotypic data and associated metadata from individ-
ual isolates and be easily maintained, accessed and queried. The plat-
form should contain the current wealth of knowledge that is located
in disparate databases located in multiple research centers from around
the world. But it will also be critical to validate the consistency and
quality of the data added to the platform, and organize and maintain
contemporaneous validated datasets. This will be especially important
for data related to off-label use of repurposed drugs currently used to
treat TB (Sotgiu and Migliori, 2015).Since 2002 there has been a gradual, 1.3% per year, decrease in the
incidence of tuberculosis (TB) worldwide. Though this is encouraging,
this level of reduction will not meet the goal of the World Health
Organization (WHO) to eliminate TB by 2050. In addition, the problem
is only being compounded by the growing incidence of drug-resistant
tuberculosis (Dye et al., 2013). Keys to the effective control of TB and
the spread of drug resistant strains include the quick and accurate pro-
curement of drug susceptibility information from patient samples that
are infected withMycobacterium tuberculosis complex (MTBC), linkage
to appropriate treatment regimens, and follow-up to ensure cure
(Wells et al., 2013). Phenotypic culture-based solutions, although the
current “gold standard”, are cumbersome, time-consuming, and conse-
quently have a high percentage of loss to follow-up. Furthermore,
culture-based solutions expose laboratory workers to potential risk of
infection and certain drugs have assay reproducibility and accuracy con-
cerns. Moreover, there are a multitude of phenotypic tests using differ-
ent methods and growth media which result in discordant phenotypic
results depending on the drug being tested. Detection of resistance con-
ferring mutations by molecular methods is a promising alternative, but
there is a paucity of information that correlates the infecting MTBC
strain's genotype to phenotype and ultimately to patient outcomes
(Noor et al., 2015).
To take better advantage of the present and emerging knowledge on
genetic patterns encoding for drug resistance, there is a need to estab-
lish a sustainable data sharing platform and associated bioinformatic. This is an open access article underTo prevent drug selection pressure from nurturing the development
of resistance in treated populations, it will be imperative to align the roll
out of new drug (Evangelopoulos and McHugh, 2015) and drug regi-
mens (Fig. 1) with novel diagnostic tools to monitor drug resistance.
Furthermore, drug developers need to revise their informed consent
in these trials so that MTBC isolated from treated patients can be used
in research to further dissect clinically relevant drug resistance mecha-
nisms. The propermanagement of drug resistance is more cost effective
than developing new anti-infective drugs and will secure the efﬁcacy of
these newly developed antimicrobials for the future.
The currently available genotypic and correlated phenotypic data
concerning the resistance of MTBC have not been vetted or validated
in a standardizedmanner, nor have themultiple data sets beenmerged.
Moreover, many of the data sets are not curated (in terms of quality
control) and may not be properly maintained. Clinical information
(e.g., treatment outcome) is present only sporadically. Therefore, the
ﬁrst challenge lies in the development of a well-structured data plat-
form that integrates high-quality sequencing data using a uniﬁed stan-
dardized pipeline from different research centers together with the
relevant complementary information including associated drug suscep-
tibility testing phenotypes, minimal inhibitor concentrations, resistance
associatedmutations, single nucleotide polymorphisms (SNPs), and ad-
ditional clinical outcome data. While a limited set of genetic resistance
markers for tuberculosis drugs has been identiﬁed, knowledge gaps
still exist which impede the broader use of genomic information for
the prediction of drug resistance (Salamon et al., 2015).
With the introduction of new drug combinations and regimens,
and patients with potentially more complex resistance proﬁles, it
is imperative to understand SNPs and genotypic information, and their
correlation with phenotypic resistance, in order to allow for the imple-
mentation of correct, personalized therapies in a rapid, individualthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Landscape of current and planned tuberculosis drug and new drug regimen clinical trials. A representation of various TB trials that are in analysis (green bars), began prior to 2015
(light blue bars), initiated in 2015 (dark blue bars), and not yet started (yellow bars). Abbreviations: DDI, drug–drug interaction; DS, drug sensitive; MDR, multi-drug resistant; ped,
pediatric; PK, pharmacokinetic. Drug abbreviations: CLR, clarithromycin; DEL, delamanid; EMB, ethambutol; INH, isoniazid; LEV, levoﬂoxacin; LZD, linezolid; MXF, moxiﬂoxacin; PRE,
pretomanid; PZA, pyrazidamide.
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relationship and mechanisms of resistance in MTBC, we do have an un-
derstanding of the correlation between genotype and phenotypic resis-
tance. Despite a wealth of current knowledge, new genotypic and
phenotypic information is evolving which will provide higher conﬁ-
dence in the relationship between a speciﬁc SNP and phenotypic drug
resistance. However, this information can only be effectively utilized if
there is a centralized data platform available. Such a platform including
a uniﬁed analysis pipeline must be vetted and accepted by the TB
community, researchers, developers, clinicians, and patients to the
point that it can become a sustainable platform.
New sequencing technologies are providing an ever increasing ava-
lanche of genomic information at continuously lower cost. However, the
use of this information is lagging for a number of reasons. Firstly, there
is a lack of understanding of the clinical signiﬁcance of the genomic
data and the complex mutual interdependence of speciﬁc mutations.
Secondly, some polymorphisms are either synonymous, i.e. unlikely as-
sociated with resistance, or are lineage speciﬁc markers. Finally, there
are challenges in analyzing the data which include the lack of validated
references and suitable validated interpretation tools. This is especially
important when considering the underlying complex genetic interac-
tions, like epistatic effects, for different mutations on drug resistance
(Fenner et al., 2012). These challenges will further increase as the
data creation continues to outpace the capabilities for data collection,
organization, analysis and interpretation.
The ReSeqTB data sharing platform is a potential solution (Starks
et al., 2015). The platform is being designed and developed by a unique
collaboration betweenWHO, US CDC, NewDiagnosticsWorking Group,
Critical Path Institute, FIND and a number of academic TB experts. The
goal of this initiative is to design, develop, populate andmake a sustain-
able data sharing platform which will be used to aggregate genotypic,
phenotypic and associated meta-data for MTBC. The initiative has
been developed in a phased manner with the ﬁrst set of objectivescentered on the design and development of the platform and the expan-
sion of an initial characterization of SNPs that have been observed in
MTBC. Raw sequencing data obtained from contributors will be curated,
standardized and aggregated through a uniﬁed pipeline. In exchange for
their data, contributors will receive ongoing access to high-quality
curated, annotated, globally aggregated datasets which can be utilized
for database interrogation, pertinent statistical data correlations, and
meaningful data outcomes and applications. As a further incentive,
their contributions will result in individual and institutional researcher
acknowledgement by way of credit within relevant publications.
Accelerated development of the proposed advanced bioinformatic
tools for use with the ReSeqTB platform is possible due to the comple-
mentary skills of the partners in the initiative bringing together subject
matter experts in data warehousing, scientiﬁc experts, and end users
who will test and improve the tools in an iterative manner. Plans are
also in development to allow researchers access to raw data to acceler-
ate the development of newproducts and to improve casemanagement
in the clinical setting. The ReSeqTB platform can be utilized tominimize
diagnostic costs, advance the research agenda and reduce testing
times which could ultimately beneﬁt patients, through advances in
basic research (sequencing of resistance genes) to clinical research
(identiﬁcation of new drug targets), new diagnostic products (faster
diagnosis of resistant bacteria and viruses), improved medical treat-
ment (avoidance of antibiotic resistance due to inadequate drugs
and dosages) and reduced health expenditures on a national level
(avoidance of expensive 2nd and 3rd line drug treatments) (Table 1).
Initial results are already indicating new, but alsomore complex an-
swers to the question of the genetic foundations of antibiotic resistance,
as demonstrated by the discovery of additional putative genes and the
indication of intergenic non-coding regions associated with drug resis-
tance (Walker et al., 2015). The ReSeqTB platform will make it possible
to better understand the underlying biology governing complex resis-
tance proﬁles, to foster development of more powerful and targeted
Table 1
Stakeholder needs and beneﬁt analysis.
Stakeholder Interests Needs Beneﬁts
Patient • Proper, accurate and effective treatment of their MTBC
infection
• Rapid development and deployment of assays for the accurate and
sensitive detection of MTBC resistance
• New and more effective therapeutic regimens for resistant MTBC and
for decreasing the potential for developing resistance
• Faster and more accurate diagnosis of drug resistant MTBC
• More appropriate and effective therapeutic regimens for drug
resistant MTBC
• More effective therapeutic regimens for non-resistant MTBC
which decreases the potential for resistance
Individual academic
data contributor
• Basic research in drug resistance mechanisms
• Basic research in drug development
• Access to high quality, curated, annotated, globally aggregated data sets
for research purposes
• Ability to utilize the data sets for new investigations
• Access to the results of raw data processed through the uniﬁed pipeline
• Access to data analysis tools (long term deliverable)
• Virtual collaborative environment
• Co-authorship on output which utilizes their data
Pharma co. data
contributor
• Access and utilization of high quality, curated, annotated,
globally aggregated data sets for research purposes
• Access to high quality, curated, annotated, globally aggregated data sets
for research and development purposes
• Access to the results of raw data processed through the uniﬁed pipeline
• Ability to analyze sequence data from clinical trials
• Access to data analysis tools (long term deliverable)
• CDISC standardized datasets
• Ability to compare analyzed clinical trial data against high
quality, curated, annotated, globally aggregated data sets and
validated resistance associated mutation sets
DST developer end
user
• Validated list of resistance associated mutations
• Interpretation/meaning of resistance associated mutations
• Access to high quality, curated, annotated, globally aggregated data sets
for research and development purposes
• Access to the results of raw data processed through the uniﬁed pipeline
• CDISC standardized datasets
• Curated database of MTBC genomic sequences
• Validated list of resistance associated mutations with associated
reference and supporting data
Research end user • Access and utilization of high quality, curated, annotated,
globally aggregated data sets for research purposes
• Ability in a controlled and validated manner to reanalyze MTBC se-
quence data
• Ability to compare analysis data against a validated set of resistance
associated mutations for MTBC
• Ability to download the aggregated ReSeqTB Database
• Access to data analysis tools for new investigations (long term
deliverable)
• Consensus driven interpretation of MTBC sequence data
• Ability to data mine an MTBC sequence database of high quality
curated annotated globally aggregated data sets
Treatment advocacy
group
• Patient treatment with the ‘best’ regimen possible based upon
the patient's sequence data
• Validated resistance associated mutation list that is updated as often as
possible and which develops the list for new drugs and drug regimens
prior to the their general implementation
• Proactive database of validated resistance associated mutations
(updated prior to release of new drugs and drug regimens)
Funding organizations • Impact on funded projects • Guidance information and materials to allow for proper assessment of
proposals
• Metrics for assisting in the measure of impact for funded proposals
• Validated, consensus driven database and analysis pipeline for
funded proposals in MTBC sequencing projects
High burden and low
burden country's
ministries of health
• Tools for increasing the effectiveness of treatment in such a
manner that improves overall treatment outcomes and de-
creases the economic impact of treatment
• Decreasing the rate of infection for MTBC and drug resistant MTBC
• Tools for increasing the effectiveness of treatment
• Active MTBC surveillance
• Potential for beneﬁcial economic impact on the diagnosis and
treatment of drug resistant MTBC
• Validated list of resistance associated mutations with associated
reference and supporting data
• Increased impact with sequence based surveillance studies
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1265M. Schito, D.L. Dolinger / EBioMedicine 2 (2015) 1262–1265drugs, to provide timely and personalized therapies and to contribute to
current surveillance efforts. Ultimately, ReSeqTB will help to ﬁght the
further spread of drug resistant strains within a community by facilitat-
ing the potential for guided and personalized therapeutic regimens
which cannot be achieved with presently available approaches.
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